logo
AAT Bioquest

Screen Quest™ Fluorimetric Neutrophil Elastase Inhibitor Screening Kit

The NE Inhibitor dose response was measured using the Screen Quest™ Fluorimetric Neutrophil Elastase Inhibitor Screening Kit on a 96-well solid black microplate with a Gemini microplate reader (Molecular Devices) Ex/Em = 360/470 nm (Cutoff = 430 nm).
The NE Inhibitor dose response was measured using the Screen Quest™ Fluorimetric Neutrophil Elastase Inhibitor Screening Kit on a 96-well solid black microplate with a Gemini microplate reader (Molecular Devices) Ex/Em = 360/470 nm (Cutoff = 430 nm).
The NE Inhibitor dose response was measured using the Screen Quest™ Fluorimetric Neutrophil Elastase Inhibitor Screening Kit on a 96-well solid black microplate with a Gemini microplate reader (Molecular Devices) Ex/Em = 360/470 nm (Cutoff = 430 nm).
Ordering information
Price
Catalog Number
Unit Size
Quantity
Add to cart
Additional ordering information
Telephone1-800-990-8053
Fax1-800-609-2943
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
ShippingStandard overnight for United States, inquire for international
Request quotation
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
UNSPSC12352200
Related products
Screen Quest™ Membrane Potential Assay Kit *Orange Fluorescence*
Screen Quest™ Membrane Potential Assay Kit *Red Fluorescence*
Screen Quest™ 10X cell staining buffer with Phenol Red Plus™
Screen Quest™ 10X calcium assay buffer with Phenol Red Plus™
Screen Quest™ Luminometric Calcium Assay Kit
Screen Quest™ Fluo-8 Medium Removal Calcium Assay Kit *Optimized for Difficult Cell Lines*
Screen Quest™ Fluo-8 No Wash Calcium Assay Kit
Screen Quest™ Fura-2 No Wash Calcium Assay Kit
Screen Quest™ Rhod-4 No Wash Calcium Assay Kit *Medium Removal*
Screen Quest™ Rhod-4 No Wash Calcium Assay Kit
Screen Quest™ Fluorimetric MDR Assay Kit
Screen Quest™ Colorimetric Chloride Channel Assay Kit
Screen Quest™ Colorimetric ELISA cAMP Assay Kit
Screen Quest™ Fluorimetric ELISA cAMP Assay Kit
Screen Quest™ TR-FRET No Wash cAMP Assay Kit
Screen Quest™ Live Cell cAMP Assay Service Pack
Screen Quest™ Fluorimetric Fatty Acid Uptake Assay Kit
Screen Quest™ Fluorimetric Glucose Uptake Assay Kit
Screen Quest™ Colorimetric Glucose Uptake Assay Kit
Screen Quest™ HEK-CNGC-Amylin 3 Receptor Cells
Screen Quest™ HEK-CNGC-Cannabinoid Receptor 1 Cells
Screen Quest™ CHO-Ga16- Chemokine (C-C) Receptor 2B Cells
Screen Quest™ HEK-CNGC-Chemokine (C-X-C motif) Receptor 4 Cells
Screen Quest™ HEK-CNGC-Dopamine Receptor 1 (DRD1) Cells
Screen Quest™ HEK-CNGC-Glucagon-like Receptor 1 (GLP1R) Cells
Screen Quest™ HEK-CNGC-Opiate Receptor-like 1 (ORL1) Cells
Screen Quest™ Human Nociceptin Receptor Ga16 coupled CHO Cells (NOP-Ga16)
Screen Quest™ CHO-Gqi Chimera Cell line
Screen Quest™ CHO-Gqo Chimera Cell line
Screen Quest™ CHO-Gqz Chimera Cell line
Screen Quest™ CHO-Gqs Chimera Cell line
Screen Quest™ CHO-Ga16 Chimera Cell line
Screen Quest™ Fluo-4 No Wash Calcium Assay Kit
Screen Quest™ No Wash Potassium Channel Assay Kit
Screen Quest™ Calbryte-520 Probenecid-Free and Wash-Free Calcium Assay Kit
Screen Quest™ Calbryte-590 Probenecid-Free and Wash-Free Calcium Assay Kit
Show More (26)

OverviewpdfSDSpdfProtocol


The Screen Quest™ Fluorimetric Neutrophil Elastase Inhibitor Screening Kit offers a fast, sensitive, and high-throughput method for screening and characterizing potential inhibitors of NE. This assay measures the NE activity based on hydrolysis of the substrate, producing a fluorescent product with Ex/Em=360/470nm. The amount of fluorescent product is directly proportional to the enzymatic activity of the neutrophil elastase present in the sample. Neutrophil elastase, also known as leukocyte elastase, ELANE, ELA2, elastase 2, neutrophil, elaszym, serine elastase, subtype human leukocyte elastase (HLE) is a cytotoxic Serine Protease with a broad substrate specificity. Azurophil granules of neutrophil store NE and release them in response to multiple stimuli like pathogens, immune complexes, or chemotactic agents such as PMA causing degradation of a range of extracellular matrix proteins, including fibronectin, laminin, proteoglycans, collagens, and elastin. NE hydrolysis accounts for approximately 80% of the total protease hydrolysis activity in the human body. Disease implications of NE include cystic fibrosis, COPD, lung emphysema, rheumatoid arthritis, and adult respiratory distress syndrome. NE has also been associated with lung injury seen in COVID-19.

Platform


Fluorescence microplate reader

Excitation360 nm
Emission470 nm
Cutoff430 nm
Recommended plateSolid black

Components


Example protocol


AT A GLANCE

Protocol Summary
  1. Prepare the NE enzyme solution (40 μL/well).

  2. Prepare the NE inhibitor serial dilution, and add 10 μL/well.

  3. Incubate the NE enzyme with inhibitor for 5-10 minutes at 37 °C.

  4. Add 50 µL of the NE working solution.

  5. Incubate at room temperature for 10-30 minutes.

  6. Monitor fluorescence intensity at Ex/Em = 360/470 nm, Cutoff = 430 nm.

Important Note

Thaw all the kit components at room temperature before starting the experiment.

PREPARATION OF STOCK SOLUTIONS

Unless otherwise noted, all unused stock solutions should be divided into single-use aliquots and stored at -20 °C after preparation. Avoid repeated freeze-thaw cycles

NE Enzyme Stock Solution
  1. Add 50 µL of the NE Assay Buffer (Component D) to the vial of NE Enzyme (Component B) to make a 100 µg/mL NE Enzyme stock solution. Mix well by pipetting, aliquot, and store at -80 °C.

    Note: Must be used within 1 week of reconstitution. Avoid freeze/thaw cycles.

PREPARATION OF STANDARD SOLUTIONS

For convenience, use the Serial Dilution Planner:
https://www.aatbio.com/tools/serial-dilution/11802

NE Inhibitor Standard
Add 1.6 µL of NE Inhibitor (Component C) to 200 µL of NE Assay Buffer (Component D) to create an 80 µM NE Inhibitor solution (STD7). Take 100 µL of the STD7 solution and perform 1:2 serial dilutions using NE Assay Buffer (Component D). This process will produce a series of NE Inhibitor standards from STD7 to STD1.

PREPARATION OF WORKING SOLUTION

NE Enzyme Working Solution
  1. Take 5 μL of the 100 μg/mL NE Enzyme stock solution and add it to 495 μL of NE Assay Buffer (Component D) to create a 1 μg/mL NE Enzyme solution.

    Note: The concentration of the NE Enzyme solution needs to be optimized when using a different inhibitor.

NE Substrate Working Solution
  1. Add 25 µL of NE Substrate (100X) (Component A) to 5 mL of NE Assay Buffer (Component D), and mix well.

    Note: Prepare the NE working solution fresh before each experiment, and protect it from light.

    Note: A 5 mL solution is sufficient for 100 tests. Adjust the amount of NE working solution proportionally to match the number of tests you need.

SAMPLE EXPERIMENTAL PROTOCOL

Table 1. Layout of NE inhibitor serial dilution and test samples in a 96-well solid black microplate. (STD = NE Inhibitor Standards (STD1-STD7, 1.25-80 µM), BL= Blank Control, TS = Test Samples.)

Positive Control
Positive Control
TS
TS
STD 1
STD 1
...
...
STD 2
STD 2
...
...
STD 3
STD 3
BL
BL
STD 4
STD 4
STD 5
STD 5
STD 6
STD 6
STD 7
STD 7

Table 2. Reagent composition for each well.

Well
Volume (Total 50 µL)
STD 1-STD 7
40 µL NE Enzyme Solution + 10 µL NE Inhibitor Serial Dilution
BL
40 µL NE Enzyme Solution + 10 µL NE Assay Buffer
GGT Positive Control
50 µL NE Assay Buffer
TS
40 µL NE Enzyme Solution + 10 µL of Inhibitor Test Sample
  1. Prepare NE Inhibitor standards (STD1-7), blank controls (BL), positive control, and test samples (TS) as outlined in Tables 1 and 2. For a 384-well plate, use 25 µL of reagent per well instead of 50 µL.

  2. Incubate the NE enzyme with inhibitor for 5-10 minutes at 37 ⁰C.

  3. Add 50 µL of NE Substrate Working Solution to each well containing the NE Inhibitor standards (STD1-STD7), blank control, positive control, and test samples. For a 384-well plate, add 25 µL of GGT Working Solution to each well instead.

  4. Incubate for 10-30 minutes at 37 °C, protected from light.

  5. Monitor the fluorescence intensity with a fluorescence microplate reader at Ex/Em = 360/470 nm (Cutoff = 430 nm).

Images


References


View all 50 references: Citation Explorer
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis.
Authors: Lulla, Amriti R and Akli, Said and Karakas, Cansu and Caruso, Joseph A and Warma, Lucas D and Fowlkes, Natalie W and Rao, Xiayu and Wang, Jing and Hunt, Kelly K and Watowich, Stephanie S and Keyomarsi, Khandan
Journal: Molecular cancer therapeutics (2024): 492-506
Human neutrophil elastase inhibitors: Classification, biological-synthetic sources and their relevance in related diseases.
Authors: Ocampo-Gallego, Jhonnatan Styver and Pedroza-Escobar, David and Caicedo-Ortega, Ana Ruth and Berumen-Murra, María Teresa and Novelo-Aguirre, Ana Lucía and de Sotelo-León, Rebeca Denis and Delgadillo-Guzmán, Dealmy
Journal: Fundamental & clinical pharmacology (2024): 13-32
Elevated first-trimester neutrophil elastase and proteinase 3 increase the risk of gestational diabetes mellitus and adverse fetal outcomes.
Authors: Wang, Lihong and Zhou, Zhoujunhao and Xu, Xinming and Li, Yue and Zhang, Rui and Yu, Zhiyan and Huang, Xinmei and Zang, Shufei and Sun, Tiange
Journal: Reproductive biology and endocrinology : RB&E (2024): 2
Neutrophil Elastase Degrades Histone Deacetylases and Sirtuin 1 in Primary Human Monocyte Derived Macrophages.
Authors: Zheng, Shuo and Bulut, Gamze B and Kummarapurugu, Apparao B and Ma, Jonathan and Voynow, Judith A
Journal: International journal of molecular sciences (2024)
Botulinum toxin type A ameliorates rat dorsal root ganglia neuron pyroptosis in postherpetic neuralgia by upregulating cathelicidin antimicrobial peptide to inhibit neutrophil elastase.
Authors: Wan, Quan
Journal: Chemical biology & drug design (2024): e14406
Targeting neutrophil elastase is a promising direction for future cancer treatment.
Authors: Jia, Wangqiang and Mao, Yudong and Luo, Qianwen and Wu, Jiang and Guan, Quanlin
Journal: Discover oncology (2024): 167
The beneficial effects of neutrophil elastase inhibitor on gastrointestinal dysfunction in sepsis.
Authors: Sun, Jia-Kui and Li, Jing-Jing and Deng, Yi-Hang and Yin, Xiang and Huangfu, Xiao-Tian and Ye, Zi-Yu and Zhou, Xue-Hui and Chen, Yong-Ming and Yuan, Shou-Tao and Wang, Xiang
Journal: Clinical and translational science (2024): e13829
Position-specific N- and O-glycosylation of the reactive center loop impacts neutrophil elastase-mediated proteolysis of corticosteroid-binding globulin.
Authors: Chernykh, Anastasia and Abrahams, Jodie L and Grant, Oliver C and Kambanis, Lucas and Sumer-Bayraktar, Zeynep and Ugonotti, Julian and Kawahara, Rebeca and Corcilius, Leo and Payne, Richard J and Woods, Robert J and Thaysen-Andersen, Morten
Journal: The Journal of biological chemistry (2024): 105519
Neutrophil Elastase as a Predictor of Delivery in Pregnant Women with Preterm Labour.
Authors: Eleje, George Uchenna and Nwagha, Uchenna Ifeanyi and Ezebialu, Ifeanyichukwu Uzoma and Ugwu, Emmanuel Onyebuchi and Ekwuazi, Kingsley Emeka and Ikechebelu, Joseph Ifeanyichukwu and Ezugwu, Euzebus Chinonye and Eke, Ahizechukwu Chigoziem
Journal: Exploratory research and hypothesis in medicine (2024): 1-9
Neutrophil Elastase Inhibition by Sivelestat (ONO-5046) Attenuates AngII-Induced Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice.
Authors: Hada, Yoshiko and Uchida, Haruhito A and Okamoto, Shugo and Otaka, Nozomu and Katayama, Katsuyoshi and Subramanian, Venkateswaran and Daugherty, Alan and Wada, Jun
Journal: American journal of hypertension (2024): 349-357